Novartis wins FDA OK for radiopharmaceutical drug, cashing in on Endocyte deal

The approval of Pluvicto for prostate cancer is a notable step forward for the field of radiopharmaceutical therapy and validates the Swiss drugmaker’s $2.1 billion buyout of Endocyte in 2018.